Trial Profile

A Phase II, Randomized, Multi-center Study, Assessing Value of Adding Everolimus (RAD001) to Trastuzumab as Preoperative Therapy of HER-2 Positive Primary Breast Cancer Amenable to Surgery

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Trastuzumab (Primary)
Indications Early breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms RADHER

Most Recent Events

02 Apr 2022 This trial has been completed in France, according to European Clinical Trials Database record.
07 Jun 2016 Results assessing predictive value of intratumoral signaling presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
14 Dec 2013 Results for the effect of treatment on biomarkers presented at the 36th Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com